Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)
Matthew J. Rees(Mayo Clinic), Hang Quach(The University of Melbourne), M Hasib Sidiqi(Curtin University), Jessica Heenan(Launceston General Hospital), Jane S. Hocking(Melbourne Health), Rosemary Harrup(University of Tasmania), Deepmala Mazumdar(Australasian Leukaemia and Lymphoma Group), William Renwick(The Royal Melbourne Hospital), Georgia McCaughan(UNSW Sydney), Belinda Butcher(UNSW Sydney), Richard Eek, Noemi Horvath(South Australia Pathology), Douglas Stuart Lenton(St. Joseph Hospital), Nicole Wong Doo(The University of Sydney), Philip Campbell(Barwon Health), Nicole Chien(Auckland City Hospital), Masa Lasica(St Vincent's Hospital Melbourne), Peter Mollee(The University of Queensland), Anna Kalff(The Alfred Hospital), Hock Choong Lai(Cancer Council Queensland), David Routledge(Peter MacCallum Cancer Centre), Sher Gul Gazdar(Australasian Leukaemia and Lymphoma Group), Michael Löw(Monash Medical Centre)
Cited by 3
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
|Nature Reviews Nephrology|2018|544
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2023|538